Compare UPBD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | CMPX |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 927.5M |
| IPO Year | 1996 | 2020 |
| Metric | UPBD | CMPX |
|---|---|---|
| Price | $17.32 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $32.25 | $14.57 |
| AVG Volume (30 Days) | 783.4K | ★ 11.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $4,695,061,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.47 | $934.41 |
| P/E Ratio | $29.51 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $1.61 |
| 52 Week High | $28.03 | $6.88 |
| Indicator | UPBD | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 27.94 |
| Support Level | $17.05 | $1.61 |
| Resistance Level | $19.26 | $3.68 |
| Average True Range (ATR) | 0.78 | 0.26 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 8.97 | 9.57 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.